![Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial - The Lancet Infectious Diseases Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/6864f1c9-715f-43f2-af0b-db0abf847c8d/gr1_lrg.gif)
Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial - The Lancet Infectious Diseases
![Diagnostics | Free Full-Text | Ivermectin for Prophylaxis and Treatment of COVID-19: A Systematic Review and Meta-Analysis Diagnostics | Free Full-Text | Ivermectin for Prophylaxis and Treatment of COVID-19: A Systematic Review and Meta-Analysis](https://www.mdpi.com/diagnostics/diagnostics-11-01645/article_deploy/html/images/diagnostics-11-01645-g005.png)
Diagnostics | Free Full-Text | Ivermectin for Prophylaxis and Treatment of COVID-19: A Systematic Review and Meta-Analysis
![Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial - The Lancet Infectious Diseases Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/6a2120e9-f195-4031-a448-bf779ad1ad9b/gr1_lrg.gif)
Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial - The Lancet Infectious Diseases
![Viruses | Free Full-Text | Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon Viruses | Free Full-Text | Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon](https://www.mdpi.com/viruses/viruses-13-00989/article_deploy/html/images/viruses-13-00989-g001-550.jpg)
Viruses | Free Full-Text | Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon
![A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness - International Journal of Infectious Diseases A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness - International Journal of Infectious Diseases](https://www.ijidonline.com/cms/asset/a81cef33-ec9b-424d-bde6-87b52c5932b1/gr1.jpg)
A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness - International Journal of Infectious Diseases
![Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial - The Lancet Infectious Diseases Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/b7188a0d-00b4-4607-9e23-3ec50a18bad4/gr1.gif)
Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial - The Lancet Infectious Diseases
![Ivermectin: potential candidate for the treatment of Covid 19 | The Brazilian Journal of Infectious Diseases Ivermectin: potential candidate for the treatment of Covid 19 | The Brazilian Journal of Infectious Diseases](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/S1413867020300817:gr1.jpeg?xkr=ue/ImdikoIMrsJoerZ+w9/qSCRz5Ib+l7k+w1jVIYLy+x9hT2kumM6W8qgi/U+qBPINCCw2U5cEUQ2m2k9UaaZ1H4iH9A4Cuabd/p4D4zLEy/4nE8N9v9ob1FvuoWvhBfRwgDH6KOrr/eQdrkchPben6xtfN4uXQZwctJ0jr1UN9080hhqitjkfhi7NFDobXscS9KYZ1FURLBsPDSSWMLw7oXO/zC86+WiFOk+6nifdfewdgkza/JMmJJGpdGkLRVui4ilAUrBVFFGfv0q4iGuTkD99HLHKFT3WuNItHEjI=)
Ivermectin: potential candidate for the treatment of Covid 19 | The Brazilian Journal of Infectious Diseases
![Lack of detectable short-term effects of a single dose of ivermectin on the human immune system - Center for Tropical and Emerging Global Diseases Lack of detectable short-term effects of a single dose of ivermectin on the human immune system - Center for Tropical and Emerging Global Diseases](https://ctegd.uga.edu/files/2021/06/13071_2021_4810_Figa_HTML.jpg)